Latest papers

Exenatide and renal failure.

The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics

[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].

Choosing among the incretin agents and why it matters.

Exendin-4 regulates pancreatic ABCA1 transcription via CaMKK/CaMKIV pathway.

Liraglutide for type 2 diabetes?

Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.

[New hypoglycemic agents in type 2 diabetes]

Clinical experience with exenatide in a routine secondary care diabetes clinic.

The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats.

Exenatide and weight loss.

New therapeutic options: management strategies to optimize glycemic control.

Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic.

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Anticancer potential of animal venoms and toxins.

[Animal toxins and human disease: from single component to venomics, from biochemical characterization to disease mechanisms, from crude venom utilization to rational drug design].

[Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].

The birdlike raptor Sinornithosaurus was venomous.

High-molecular weight protein toxins of marine invertebrates and their elaborate modes of action.

Insect venoms.